Trial · NCT02719574
Participant flow153
How many started, completed or left each group, period by period.
1 to 20 of 153
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | 3 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | 8 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | 7 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | 4 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | 7 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | 8 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 1; FT-2102 (Single Agent) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 2; FT-2102 (Single Agent) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 3; FT-2102 (Single Agent) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 7; FT-2102 (Single Agent) | 0 | |
| Phase 1 (Dose Escalation) | STARTED | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) | 0 | |
| Phase 1 (Dose Escalation) | COMPLETED | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | 0 | |
| Phase 1 (Dose Escalation) | COMPLETED | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | 0 | |
| Phase 1 (Dose Escalation) | COMPLETED | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02719574/flow